President Trump stands a chance of creating a new economic world order in his China trade fight, says the chief economic advisor of Allianz.Economyread more
Most U.S. hedge funds aren't expecting another big stock market sell-off as more firms curb bets on volatility, according to Nomura.Marketsread more
A sell-off in chip stocks intensified following a report that chipmakers are cutting ties with Huawei after the Trump administration's ban.Marketsread more
Ford Motor said Monday that it is laying off about 7,000 salaried workers, about 10% of that global workforce, as part of a restructuring plan designed to save the No. 2...Autosread more
Google announced Google Glass Enterprise Edition 2 on Monday, a new set of smart glasses that's catered toward businesses and costs $999. Google has focused on business use...Technologyread more
More than 170 shoe retailers, including Nike, Under Armour, Adidas, Foot Locker, Ugg and Off Broadway Shoe Warehouse, have penned a letter to the White House asking President...Retailread more
Microsoft on Monday announced new moderation for its Xbox platform in an effort to cut down on toxic content and to make gaming safer for everyone.Technologyread more
Before the winner would even get a dime, more than $54 million would be withheld for federal taxes. Much more would likely be due at tax time.Personal Financeread more
People investing in some technology stocks should not expect them to go up anytime soon, warns the "Mad Money" host.Investingread more
The finalists from the Council for Economic Education's National Economics Challenge will put their problem-solving skills to the test Monday in a high school economics...US Economyread more
The company said in an open letter to shareholders, its board of directors are "confident" the drugmakers acquisition of Celgene is the best path forward. The board argued the Celgene transaction will ensure the company's "strong growth continues for the foreseeable future" and will immediately establish market leadership in oncology.
"We undertook a robust and comprehensive review of our core business and strategic expansion opportunities potentially available to the company and identified the Celgene acquisition as the most attractive opportunity for shareholder value creation," the company said in a release.
Bristol has sent executives to New York to meet with institutional investors several times over the last several weeks and met with investors in Boston last Wednesday and Thursday to try and salvage the deal, a person briefed on the meetings told CNBC.
Last week, hedge funds Wellington Management and Starboard Value said they do not approve the blockbuster deal.
Wellington — which is Bristol's largest institutional holder with 135.3 million shares, or 8 percent, of its common stock — said the Celgene deal asks Bristol shareholders to accept too much risk. Starboard, which holds about 1 million shares, cited similar concerns, saying the Celgene deal was "poorly conceived and ill-advised."
Starboard said Wednesday it mailed a letter to Bristol shareholders, reiterating its belief that the deal is not in shareholders' best interests.
The deal was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol's balance sheet while assuming $20 billion in Celgene's debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.
Buying Celgene gives Bristol more cancer drugs at a time when its immuno-oncology portfolio struggles to keep up with rival Merck's
Shareholders will vote on the proposed acquisition next month.
The company on Wednesday reiterated that it expects the transaction to close in the second half of this year.